Market Opportunity

Gateway is trusted with public funding from the National Institutes of Health to conduct scientific research. Private investments propel our expansion in the market.

Top-down view of street and park in Saint Louis. Investment opportunity. Gateway biotechnology.

Hearing loss affects 600 million people globally and nearly 40 million Americans. Hearing loss is often caused by noise exposure, normal aging processes, and as a side-effect of injury or chemotherapy. Tinnitus is highly associated with hearing loss and it affects 15% of people and can cause stress, anxiety, depression, lack of sleep, and even suicidal tendencies. Currently, there are no FDA-approved drugs to prevent or treat hearing disorders such as hearing loss and tinnitus.

Foresight Science & Technology performed a niche analysis for Gateway Biotechnology, Inc. in 2015 after the company secured NIH funding. They estimated the market size for noise-induced hearing loss alone to be $317.4 million with a 3.3% annual growth rate.

“Gateway Biotechnology Inc. is developing products for which there is great need. The market for this product type is diverse, with a range of industrial, military and recreational applications and within certain sectors, there are strong regulatory drivers that encourage development and use of such products. The advantage of Gateway Biotechnology Inc. is that the company is taking a novel approach”

Foresight Science & Technology report

Early Achievements

The United States government and private funding agencies believe that Gateway has the ability to bridge the gap between hearing disorders and treatments. Gateway has been trusted with over $12 million in funding necessary to gather preclinical and clinical data on drug re-purposing and nutraceutical development for hearing disorders.

Gateway has also developed extensive collaborative projects with Harvard University, Northeast Ohio Medical University, University at Buffalo, University of Akron, University of Texas at Dallas, and Washington University in St. Louis.

Moving Forward

Additional investments for research and development will enable us to complete INDs for our product lines.

Partnerships with pharmaceutical companies will allow us to complete the required regulatory planning to performing clinical trials with our product lines.

If interested in discussing partnerships or investment opportunities, please contact us